Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 4/20 | 0.80 |
| ▸ | CALML3 | P27482 | 7/20 | 0.38 |
| ▸ | MAOB | P27338 | 4/20 | 0.37 |
| ▸ | F10 | P00742 | 1/20 | 0.37 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | SDHA | P31040 | 1/20 | 0.36 |
| ▸ | FADS1 | O60427 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3039167 | 0.93 | MAOA (0.87) | MAOACALML3MAOBF10LMNA | |
| SCHEMBL13515434 | 0.90 | MAOA (0.81) | MAOACALML3MAOBF10LMNA | |
| SCHEMBL5766156 | 0.89 | MAOA (1.00) | MAOACALML3MAOBF10LMNA | |
| SCHEMBL5738263 | 0.89 | MAOA (0.80) | MAOACALML3MAOBF10LMNA | |
| SCHEMBL3035242 | 0.89 | MAOA (1.00) | MAOACALML3MAOBF10LMNA | |
| SCHEMBL6040286 | 0.88 | MAOA (0.78) | MAOACALML3MAOBF10LMNA | |
| SCHEMBL3041136 | 0.88 | MAOA (0.78) | MAOACALML3MAOBF10LMNA | |
| SCHEMBL13515898 | 0.87 | MAOA (0.77) | MAOACALML3MAOBF10LMNA | |
| SCHEMBL13515466 | 0.87 | MAOA (0.77) | MAOACALML3MAOBF10LMNA | |
| SCHEMBL3038620 | 0.86 | MAOA (0.75) | MAOACALML3MAOBF10LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1660488-A1 | NOVEL ANTIMICROBIAL ARYLOXAZOLIDINONE COMPOUNDS | Warner-Lambert Company LLC (US) | 2006-05-31 | — | — | EP | claimed |
| US-20050065187-A1 | Novel antimicrobial aryloxazolidinone compounds | GORDEEV MIKHAIL FEDOROVICH (US) | 2005-03-24 | — | — | US | claimed |
| WO-2005019214-A1 | NOVEL ANTIMICROBIAL ARYLOXAZOLIDINONE COMPOUNDS | WARNER-LAMBERT COMPANY LLC (US) | 2005-03-03 | — | — | WO | claimed |
| EP-1660488-A1 | NOVEL ANTIMICROBIAL ARYLOXAZOLIDINONE COMPOUNDS | Warner-Lambert Company LLC (US) | 2006-05-31 | — | — | EP | disclosed |
| US-20050065187-A1 | Novel antimicrobial aryloxazolidinone compounds | GORDEEV MIKHAIL FEDOROVICH (US) | 2005-03-24 | — | — | US | disclosed |
| WO-2005019214-A1 | NOVEL ANTIMICROBIAL ARYLOXAZOLIDINONE COMPOUNDS | WARNER-LAMBERT COMPANY LLC (US) | 2005-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065187-A1 | Novel antimicrobial aryloxazolidinone compounds | XDH, NQO1, MPO | MAOA 144/4885CALML3 4443/4885MAOB 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.